Clinical trials: Stage II Breast Carcinoma
Breast Cancer
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
- Trial name
- LEADER (NCT03285412)
- Testing
- Ribociclib, Endocrine therapy
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Neoplasms, Breast
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer.
- Trial name
- NCT00111787
- Testing
- Lapatinib, Paclitaxel
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status.
- Trial name
- NCT00958971
- Testing
- TKI258
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057993
- Testing
- trastuzumab, exemestane
- Sponsor
- Northwestern University
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.
- Trial name
- NCT05021900
- Testing
- Tenalisib 800mg, Tenalisib 1200mg
- Where
- 3 sites in Georgia
- Volunteers
- 40 people
- Sponsor
- Rhizen Pharmaceuticals SA
Neoadjuvant Operable Breast Cancer
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
The investigators propose in the present study an innovative approach, combining the most recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and innovative diagnostic approaches such as the PAM50…
- Trial name
- NeoPAL (NCT02400567)
- Testing
- Fluorouracile, Epirubicin, Cyclophosphamide
- Where
- 2 sites in France
- Volunteers
- 125 people
- Sponsor
- UNICANCER
DCIS Grade 3, Stage I Breast Cancer
Energy Balance and Breast Cancer Aspects-II
The purpose of this study, the EBBA-II trial, is to determine whether a 12 month exercise program comprised of strength and endurance training among newly diagnosed breast cancer patients undergoing adjuvant therapy, will…
- Conditions
- DCIS Grade 3, Stage I Breast Cancer, Stage II Breast Cancer, LCIS, Lobular Carcinoma in Situ
- Trial name
- EBBA-II (NCT02240836)
- Testing
- Intervention. Exercise
- Where
- 2 sites in Norway
- Volunteers
- 545 people
- Sponsor
- Oslo University Hospital
Breast Cancer
Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32
RATIONALE: Learning about the effect of metformin hydrochloride in breast density of women with early-stage breast cancer may help plan treatment.
- Trial name
- NCT01666171
- Testing
- metformin hydrochloride, clinical observation, diagnostic laboratory biomarker analysis
- Volunteers
- 458 people
- Sponsor
- Cancer and Leukemia Group B
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
The goal of this study is to obtain preliminary evidence of the effect of 8 acupuncture treatments over 10 weeks in breast and GI cancer patients who are currently receiving or recently completed active neurotoxic chemotherapy…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03505671
- Testing
- Acupuncture Therapy, Best Practice, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer Invasive, Node Positive Breast Cancer
Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer
This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging…
- Trial name
- FAPI-PET (NCT06790264)
- Testing
- 68Ga-FAPi-46 PET/CT
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- European Institute of Oncology
Triple Negative Breast Cancer
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
- Trial name
- NCT06460298
- Testing
- ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- ProDa BioTech, LLC
Breast Cancer
Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer
The study hypothesis is that metronomic treatment is more efficient than standard treatment.
- Trial name
- XeNa (NCT01941771)
- Testing
- Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda), Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- University of Aarhus
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Leptomeningeal Metastasis of HER2-positive Breast Cancer
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis
- Trial name
- NCT07263425
- Testing
- Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Ovarian Cancer
A Mind-body Intervention to Improve Body and/or Self Image
The purpose of this study is to determine if hypnotic relaxation therapy is a more effective intervention for improving self-image in women who have been diagnosed with breast or gynecologic cancer when compared to progressive…
- Conditions
- Breast Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Trial name
- NCT02531997
- Testing
- Hypnotic Relaxation Therapy, Progressive Muscle Relaxation
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Michigan
Breast Cancer, Cancer of Breast
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Carcinoma
- Trial name
- PALTAN (NCT02907918)
- Testing
- Palbociclib, Letrozole, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, HER2-positive Breast Cancer
Tucatinib Together With Pembrolizumab and Trastuzumab
Women or men with HER2-positive, metastatic breast cancer, who have progressed on previous treatment, will receive tucatinib in combination with pembrolizumab and trastuzumab (PD-L1 positive).
- Trial name
- TUGETHER (NCT04789096)
- Testing
- Tucatinib, Pembrolizumab, Trastuzumab
- Where
- 15 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Breast Cancer Trials, Australia and New Zealand
Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC)…
- Trial name
- NCT03411161
- Testing
- Combination therapy (S81694 + paclitaxel) phase I, Paclitaxel, Combination therapy (S81694 + paclitaxel) phase II
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Institut de Recherches Internationales Servier
HER2 Negative Metastatic Breast Cancer
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer
90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to determine the difference in progression…
- Trial name
- CONCEPT (NCT03048942)
- Testing
- Cabazitaxel, Paclitaxel
- Where
- 13 sites in United Kingdom
- Volunteers
- 158 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.